Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections In Bronchiectasis
Links shared publicly online about this topic.
- 418total visits
Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections In Bronchiectasis
Aradigm Corporation (OTCBB:ARDM) announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non
View full resource at medicalnewstoday.com
Tags: Infection, Bronchiectasis, Antibiotic, Cipro, Ciprobay
Most Recently Shared on March 23, 2011 at 7:05 pm By:
Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections I... http://mnt.to/3SDy
Also Shared By:
Advertisement
MNT Cystic Fibrosis
@mnt_cysticfibro
Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections I... http://mnt.to/3SDy
1 year ago...